Chrysalis Biomedical Advisors
Chrysalis Biomedical Advisors is a six-person boutique advisory firm founded in 2016 in San Francisco, operating in the biomedical sector. Its specific service lines, client base, and revenue model could not be verified from available data.
- Company typePrivate
- Founded-
- Headquarters—
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Chrysalis Biomedical Advisors does
Chrysalis Biomedical Advisors is a small professional services firm operating in the biomedical sector, headquartered in San Francisco, CA with a reported Canadian domicile (likely a data error given the SF location). Founded in 2016, the firm operates with a team of approximately 6 employees, suggesting a boutique advisory or consulting practice rather than a product or technology company. The firm's name and the "biomedical" descriptor in its web address (chrysalisbiomed.com) imply it provides specialized advisory services — likely regulatory, strategic, scientific, or commercial — to life sciences clients such as biotech startups, medical device companies, or pharmaceutical firms, though its specific service lines could not be confirmed.
The company maintains a minimal public footprint: there are no disclosed products, no app presence, no API or technology stack details, no named customer logos, no partnerships, no awards, and no patents in the available data. Notably, the firm's own website rendered only a verification/loading page ("One moment, please...") during data collection, blocking direct extraction of service descriptions, team bios, or client references. As a result, the business model — presumably project-based or retainer-based advisory fees — is inferred from the "Advisors" suffix and headcount scale rather than documented from primary sources.
From an investment-analytic standpoint, Chrysalis Biomedical Advisors sits in a data-thin zone. The combination of a long-standing founding date (2016), small headcount (6), no disclosed funding or external investors, and no verifiable operating signals suggests a privately-held, possibly owner-operated boutique consultancy. No material strategic moves, leadership changes, M&A activity, product launches, or geographic expansions are documented in the available data. A thorough diligence process would require direct outreach to the firm, third-party credit and corporate registry searches, and reference checks with named principals to validate service offerings, client roster, and revenue base.
Chrysalis Biomedical Advisors firmographics
Firmographics- Name
- Chrysalis Biomedical Advisors
- Website
- https://chrysalisbiomed.com
- Company type
- Private
- Headcount range
- 1–10 employees
- Short description
- Chrysalis Biomedical Advisors is a six-person boutique advisory firm founded in 2016 in San Francisco, operating in the biomedical sector. Its specific service lines, client base, and revenue model could not be verified from available data.
- Ownership category
- akta.pro rank
Chrysalis Biomedical Advisors industry classification
Industry- Product category
- Biomedical Consulting
- NAICS
- Management, Scientific, and Technical Consulting Services (5416), Other Scientific and Technical Consulting Services (54169)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Medical Affairs, Scientific Communications & HEOR FSP (HLAGAOAG)
Keywords
Chrysalis Biomedical Advisors business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales
Chrysalis Biomedical Advisors product offering
Product offeringCore offering
Based solely on the firm name, Chrysalis Biomedical Advisors appears to provide advisory services to clients in the biomedical sector. The available source material contains no description of specific service lines, deliverables, or customer engagements because the firm's website displayed only a verification/loader page.
Differentiator
Problem solved
Functional benefit
Products and services
- Biomedical advisory services Based on the firm name, this appears to be the company's core offering; however, no specific service descriptions, deliverables, or named service lines are documented in the available source material.
Companies that use Chrysalis Biomedical Advisors
Customer profileIdeal customer profiles1 record
Chrysalis Biomedical Advisors technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Chrysalis Biomedical Advisors competitors and assessment
Company assessmentDirect peers
- Fishawack Health: Medical communications and HEOR consultancy serving pharma/biotech. Closely mirrors the medical affairs + scientific communications focus implied by the subject company's positioning.
- Complete HealthVizion (CHV) / IPG Health Medical Communications: Network of medical communications and scientific content agencies focused on publications, MSL support, and scientific response — direct overlap with a small biomedical advisory's likely service mix.
- ProEd Communications: Boutique medical affairs and scientific communications agency serving pharma/biotech. Closely analogous niche positioning and scale to a 6-person biomedical advisory firm.
- Envision Pharma Group: Specialized provider of medical affairs, scientific communications, and HEOR services to pharma/biotech. Direct overlap with a boutique "Biomedical Advisors" practice focused on outsourced medical affairs and scientific response work.
Broad incumbents
- ICON plc: Large CRO with FSP and medical/scientific communications capabilities. Adjacent buyer profile (biopharma R&D and medical teams) makes it a comparable incumbent for FSP-style engagements.
- Parexel International: Global CRO offering medical affairs, HEOR, regulatory, and clinical services. Provides a scaled alternative to boutique biomedical advisory engagements.
- Syneos Health: Clinical-to-commercial life-sciences services firm with medical affairs and scientific communications capability. Competes for FSP/RFP opportunities aimed at medical and scientific teams.
- Charles River Laboratories: Research and drug-discovery CRO; included as a broader life-sciences services incumbent with similar biopharma buyer base and FSP-style contracts.
- IQVIA (incl. Q² Solutions medical affairs): Global life-sciences services giant with a sizable medical affairs and HEOR FSP practice. Competes for the same buyer wallets as a small biomedical advisory; serves as the broad incumbent benchmark.
Regional players
- Medpace: Mid-sized clinical CRO based in the U.S. (Ohio HQ) with growing medical/regulatory services. Comparable buyer audience and adjacent scientific services; regional versus the SF-based subject firm.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat1 record
Key risks5 records
Key highlights4 records
Customer concentration
Chrysalis Biomedical Advisors social profiles
Digital presenceChrysalis Biomedical Advisors financial estimates
Financial estimateRevenue estimate
Valuation estimate
Chrysalis Biomedical Advisors leadership team
Management profileNumber of profiles
Chrysalis Biomedical Advisors funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Chrysalis Biomedical Advisors M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Chrysalis Biomedical Advisors
What does Chrysalis Biomedical Advisors do?
Based solely on the firm name, Chrysalis Biomedical Advisors appears to provide advisory services to clients in the biomedical sector. The available source material contains no description of specific service lines, deliverables, or customer engagements because the firm's website displayed only a verification/loader page.
When was Chrysalis Biomedical Advisors founded?
Chrysalis Biomedical Advisors was founded in -1. It employs 1 to 10 people.
Who are Chrysalis Biomedical Advisors's main competitors?
Direct peers on record are Fishawack Health, Complete HealthVizion (CHV) / IPG Health Medical Communications, ProEd Communications and Envision Pharma Group. Broad incumbents are ICON plc, Parexel International, Syneos Health, Charles River Laboratories and IQVIA (incl. Q² Solutions medical affairs). Medpace is listed as a regional player.
Does Chrysalis Biomedical Advisors have an API?
No public API is recorded for Chrysalis Biomedical Advisors.
What industry is Chrysalis Biomedical Advisors in?
Chrysalis Biomedical Advisors's product category is Biomedical Consulting. Its primary akta.pro industry code is HLAGAOAG, Medical Affairs, Scientific Communications & HEOR FSP. Its NAICS code is 5416 and its SIC code is 8731.